Immune suppressive mechanisms in the tumor microenvironment

David H. Munn, Vincenzo Bronte

Research output: Contribution to journalReview article

146 Citations (Scopus)

Abstract

Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalCurrent Opinion in Immunology
Volume39
DOIs
StatePublished - Apr 1 2016

Fingerprint

Tumor Microenvironment
Immunotherapy
Immunosuppressive Agents
Neoplasms
Myeloid Cells
Stromal Cells
Cell- and Tissue-Based Therapy
Anti-Inflammatory Agents
Lymphocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immune suppressive mechanisms in the tumor microenvironment. / Munn, David H.; Bronte, Vincenzo.

In: Current Opinion in Immunology, Vol. 39, 01.04.2016, p. 1-6.

Research output: Contribution to journalReview article

@article{f15bbe4a0dd34dfcad72c5ef4ee2ac0e,
title = "Immune suppressive mechanisms in the tumor microenvironment",
abstract = "Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.",
author = "Munn, {David H.} and Vincenzo Bronte",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.coi.2015.10.009",
language = "English (US)",
volume = "39",
pages = "1--6",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Immune suppressive mechanisms in the tumor microenvironment

AU - Munn, David H.

AU - Bronte, Vincenzo

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.

AB - Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.

UR - http://www.scopus.com/inward/record.url?scp=84947804600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947804600&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2015.10.009

DO - 10.1016/j.coi.2015.10.009

M3 - Review article

C2 - 26609943

AN - SCOPUS:84947804600

VL - 39

SP - 1

EP - 6

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -